» Articles » PMID: 16337795

Sprouty Proteins: Multifaceted Negative-feedback Regulators of Receptor Tyrosine Kinase Signaling

Overview
Specialty Cell Biology
Date 2005 Dec 13
PMID 16337795
Citations 217
Authors
Affiliations
Soon will be listed here.
Abstract

Receptor tyrosine kinases (RTKs) control a wide variety of processes in multicellular organisms, including proliferation, differentiation, migration and survival. Their activity is tightly controlled through the coordinated action of both positive and negative regulators that function at multiple levels of the signal transduction cascade, and at different time points within the growth-factor-induced response. When this process goes awry, the outcome can be developmental defects and malignancy. Sprouty (Spry) proteins represent a major class of ligand-inducible inhibitors of RTK-dependent signaling pathways. New biochemical and genetic evidence indicates specific roles of the Spry genes in development and multiple modes of action of the Spry proteins in regulation of the RTK-induced response.

Citing Articles

Complex Roles of /SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy.

Scheiter A, Lu L, Gao L, Feng G Annu Rev Cancer Biol. 2025; 8(1):15-33.

PMID: 39959686 PMC: 11824402. DOI: 10.1146/annurev-cancerbio-062722-013740.


SPROUTY2, a Negative Feedback Regulator of Receptor Tyrosine Kinase Signaling, Associated with Neurodevelopmental Disorders: Current Knowledge and Future Perspectives.

Puranik N, Jung H, Song M Int J Mol Sci. 2024; 25(20).

PMID: 39456824 PMC: 11507918. DOI: 10.3390/ijms252011043.


Multiple endocrine defects in adult-onset Sprouty1/2/4 triple knockout mice.

Altes G, Olomi A, Perramon-Guell A, Hernandez S, Casanovas A, Perez A Sci Rep. 2024; 14(1):19479.

PMID: 39174793 PMC: 11341818. DOI: 10.1038/s41598-024-70529-w.


Sprouty1 is a broad mediator of cellular senescence.

Anerillas C, Perramon-Guell A, Altes G, Cuesta S, Vaquero M, Olomi A Cell Death Dis. 2024; 15(4):296.

PMID: 38670941 PMC: 11053034. DOI: 10.1038/s41419-024-06689-4.


Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.

Bahar M, Kim H, Kim D Signal Transduct Target Ther. 2023; 8(1):455.

PMID: 38105263 PMC: 10725898. DOI: 10.1038/s41392-023-01705-z.